KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Equivalents (2018 - 2025)

Aurinia Pharmaceuticals' Cash & Equivalents history spans 7 years, with the latest figure at $80.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.86% year-over-year to $80.2 million; the TTM value through Dec 2025 reached $80.2 million, down 3.86%, while the annual FY2025 figure was $80.2 million, 3.86% down from the prior year.
  • Cash & Equivalents reached $80.2 million in Q4 2025 per AUPH's latest filing, up from $73.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $231.9 million in Q4 2021 to a low of $33.4 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $89.5 million, with a median of $81.0 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: crashed 59.39% in 2022, then surged 97.05% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $231.9 million in 2021, then plummeted by 59.39% to $94.2 million in 2022, then tumbled by 48.1% to $48.9 million in 2023, then skyrocketed by 70.71% to $83.4 million in 2024, then dropped by 3.86% to $80.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Cash & Equivalents are $80.2 million (Q4 2025), $73.2 million (Q3 2025), and $53.0 million (Q2 2025).